The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Medincell (Paris:MEDCL): This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or ...

Teva 2024 Results earnings conference call today at 8:00am ET, webcast and replay: https://events.q4inc.com/attendee/899170090 * NDA (New Drug Application): Formal ...

Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology’s reach into new molecules and indications, and potentially by potentially considering ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell ...

The Global Offering is also aimed at retail investors via PrimaryBid platform, exclusively in France. Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO ® ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...